Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma.
CD8+ T cells
HHLA2
KIRC
TCGA
tissue microarrays
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
01
2020
accepted:
31
03
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
HHLA2, a newly identified B7 family member, regulates T cell functions. However, the expression and prognostic value of HHLA2 in solid tumors is ill defined. This study aimed to reveal the expression landscape of HHLA2 in various solid tumors, and to evaluate its prognostic value in kidney clear cell carcinoma (KIRC). Using The Cancer Genome Atlas (TCGA) database, we investigated the expression pattern of HHLA2 across 22 types of cancer. HHLA2 and CD8 protein expression was determined via immunohistochemistry (IHC). KIRC-specific findings were further analyzed with R software and the prognostic value was validated on tissue microarrays. HHLA2 was widely expressed in cancers at both the mRNA and protein levels. Among all tested tumors, KIRC showed the highest transcript level of HHLA2, and HHLA2 levels were significantly higher in tumor tissues than in matched normal samples, as evidenced by both TCGA and IHC data. HHLA2 was also positively correlated with survival rates in KIRC based on TCGA and clinical data. Receiver operating characteristic curves data showed the prognostic value of HHLA2 for patients with KIRC in TCGA. Moreover, HHLA2 was positively correlated with immune-related genes, while HHLA2 and CD8 expression exhibited a consistent trend in KIRC tumor samples. In conclusion, HHLA2 is highly expressed in KIRC and predicts a favorable survival outcome, highlighting that it may work as a potential target for KIRC therapy.
Identifiants
pubmed: 32509772
doi: 10.3389/fcell.2020.00280
pmc: PMC7248229
doi:
Types de publication
Journal Article
Langues
eng
Pagination
280Informations de copyright
Copyright © 2020 Zhang, Liu, Zhang, Li, Li, Wang, Chand, Guan, Zang and Zhang.
Références
J Med Genet. 2019 Jan;56(1):43-49
pubmed: 29967134
Immunity. 2016 May 17;44(5):955-72
pubmed: 27192563
Int J Cancer. 2001 Oct 1;94(1):1-5
pubmed: 11668471
Cancer Immunol Res. 2018 Jan;6(1):69-78
pubmed: 29133290
Hepatology. 2014 Nov;60(5):1776-82
pubmed: 24912948
Clin Cancer Res. 2015 May 15;21(10):2359-66
pubmed: 25549724
Kidney Int. 2019 Aug;96(2):409-420
pubmed: 31101365
J Hematol Oncol. 2019 Nov 29;12(1):127
pubmed: 31783892
Eur Urol. 2015 Jan;67(1):85-97
pubmed: 24857407
Front Cell Dev Biol. 2020 Feb 11;8:17
pubmed: 32117960
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
J Hematol Oncol. 2018 Jan 12;11(1):8
pubmed: 29329556
Onco Targets Ther. 2018 Mar 20;11:1563-1570
pubmed: 29593422
Clin Cancer Res. 2017 Oct 15;23(20):6002-6011
pubmed: 28615369
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9879-84
pubmed: 23716685
Oncoimmunology. 2016 Jun 16;5(11):e1196310
pubmed: 27999734
Oncotarget. 2016 Jan 12;7(2):1486-99
pubmed: 26625204
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Br J Cancer. 2020 Apr;122(8):1211-1218
pubmed: 32071413
Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):E7535-E7544
pubmed: 27821766
J Hematol Oncol. 2018 Mar 15;11(1):39
pubmed: 29544515
Nat Genet. 2018 Sep;50(9):1271-1281
pubmed: 30150660
Nat Commun. 2013;4:2043
pubmed: 23784006
Nature. 2016 Nov 3;539(7627):112-117
pubmed: 27595394
Int J Cancer. 2018 Nov 15;143(10):2561-2574
pubmed: 29981155
ESMO Open. 2017 May 2;2(2):e000150
pubmed: 28761741
J Hematol Oncol. 2019 Sep 5;12(1):92
pubmed: 31488176
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
BMC Genomics. 2017 Oct 3;18(Suppl 6):678
pubmed: 28984208
Front Immunol. 2015 Aug 10;6:411
pubmed: 26322044
Trends Mol Med. 2015 Jan;21(1):24-33
pubmed: 25440090
Oncogene. 2017 Nov 2;36(44):6143-6153
pubmed: 28692048
Cancer Cell Int. 2019 Apr 16;19:101
pubmed: 31015801
Mol Cancer. 2016 Aug 24;15(1):55
pubmed: 27552968
Oncoimmunology. 2016 Mar 10;5(6):e1151594
pubmed: 27471622
Sci Rep. 2016 Aug 17;6:31154
pubmed: 27531281
Oncoimmunology. 2015 Apr 14;4(8):e1026534
pubmed: 26405587
Immunol Rev. 2017 Mar;276(1):26-39
pubmed: 28258693
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Cancer Res. 2005 Feb 1;65(3):1089-96
pubmed: 15705911
Clin Cancer Res. 2017 Feb 1;23(3):825-832
pubmed: 27553831
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Cancer Cell. 2017 Jun 12;31(6):848-848.e1
pubmed: 28609660
Cancer Lett. 2019 Feb 1;442:333-340
pubmed: 30447255
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
J Hematol Oncol. 2018 Dec 21;11(1):142
pubmed: 30577797
Nat Med. 2010 May;16(5):586-91, 1p following 591
pubmed: 20400961